Higher precision, first tier newborn screening for metachromatic leukodystrophy using 16:1-OH-sulfatide

Area of Science:

• Biochemistry
• Genetics
• Pediatrics

Background:

• Metachromatic leukodystrophy (MLD) newborn screening (NBS) traditionally uses sulfatide measurement.
• Current NBS methods show high precision but can have false positives.

Purpose of the Study:

• To evaluate a novel sulfatide biomarker for improved MLD NBS.
• To assess the accuracy and feasibility of the enhanced MLD NBS protocol.

Main Methods:

• First-tier sulfatide analysis in dried blood spots (DBS) using 16:1-OH-sulfatide.
• Second-tier arylsulfatase A activity assay in DBS.
• Validation across multiple MLD NBS centers.

Main Results:

• The 16:1-OH-sulfatide biomarker significantly reduces first-tier false positives compared to 16:0-sulfatide.
• The combined approach yields an estimated false positive rate of 0.048%, nearing zero with second-tier testing.
• All 40 tested newborn DBS from MLD patients were accurately detected, indicating a very low false negative rate.

Conclusions:

• The enhanced MLD NBS protocol using 16:1-OH-sulfatide is highly precise and accurate.
• This improved NBS method is ready for global deployment.
• The protocol can be integrated with existing newborn screening programs for multiple conditions.